Pekka Taimen
MD, PhD
pepeta@utu.fi +358 29 450 4524 +358 50 431 1353 Kiinamyllynkatu 10 Turku : D5019 : https://orcid.org/0000-0001-8849-4604 Official web page of research group |
pathology; histology; cell biology; prostate cancer, bladder cancer, cardiomyopathy, nuclear lamin
Pekka Taimen received his MD degree from the University of Turku in 2001 and defended his thesis at the Department of Pathology, University of Turku in 2004. In 2008-2009 PT worked as a postdoctoral fellow in the laboratory of Prof. Robert D. Goldman, Northwestern University Medical School, Chicago. Postdoctoral studies focusing on nuclear intermediate filament proteins called lamins were further continued as a junior group leader after returning back to Turku in early 2010. In 2011 PT received a specialist degree in Pathology and since then he has worked as a part-time specialist at the Pathology Division, Turku University Hospital with special focus on uropathology. From 2012 PT has worked as a Clinical lecturer in Pathology and between 2015-2019 as a part-time Academy of Finland Clinical Researcher. PT was appointed as a tenure track Assistant Professor of Molecular Pathology in January 2019 and an Associate Professor in August 2020. In January 2022, PT was appointed as a Professor of Molecular Pathology and he currently serves as the head of the pathology unit at the Faculty of Medicine, University of Turku.
Professor Pekka Taimen has 20 years of experience in cell and molecular biology as well as in translational research. The main focus of his research group is on human diseases caused by lamin mutations, such as cardiomyopathies and premature aging syndrome. More recently, PT has also actively worked on prostate and bladder cancer related projects including novel biomarkers, biobanking, patient derived cell lines and improved imaging techniques utilizing digital pathology and machine learning approaches.
Pekka Taimen has more than 10 years of experience in teaching medical students at the Institute of Biomedicine, University of Turku. He has served first as a university teacher and from 2012 as a clinical lecturer. In 2015 PT received the Lecturer of the Year award in the Faculty of Medicine.
- Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells (2019)
- International Journal of HyperthermiaMagnetic Resonance in Medicine
- IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy (2019)
- Journal of Magnetic Resonance Imaging
- Lamiinikardiomyopatia (2019)
- Sydänääni: Suomen Kardiologisen Seuran Lehti
- Modeling of LMNA-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem CellsSORLA regulates endosomal trafficking and oncogenic fitness of HER2 (2019)
- CellsNature Communications
- Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells (2019)
- European Urology
- Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study (2019)
- European Urology Oncology
- Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials)Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial (2019)
- Journal of Magnetic Resonance ImagingPLoS Medicine
- Quantitative Analysis of Nuclear Lamins Imaged by Super-Resolution Light Microscopy (2019)
- Cells
- Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterizationANO7 is associated with aggressive prostate cancer (2019)
- PLoS ONEInternational Journal of Cancer
- Repeatability of radiomics and machine learning for DWI: Short-term repeatability study of 112 patients with prostate cancer (2019)
- Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4 (2019)
- European UrologyCancer Imaging
- Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer (2019)
- Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment (2019)
- BJU InternationalEndocrine-Related Cancer
- Laminopatiat - harvinaisten sairauksien kasvava joukko (2019)
- (2018)
- C-11-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial) (2018)
- 2018
- (2018)
- Duodecim
- New prostate cancer grade grouping system predicts survival after radical prostatectomy (2018)
- Human Pathology
- Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice (2018)
- BMC Research Notes



